Degradation Ability Assay

Why Measure PROTAC Degradation Ability?

In targeted protein degradation (TPD) research, a compound's ability to degrade its intended target is the single most defining metric of success — yet measuring degradation accurately and meaningfully presents distinct challenges beyond traditional pharmacology. Unlike occupancy-driven inhibitors, PROTACs and other molecular degraders operate through a catalytic, event-driven mechanism where degradation depth, kinetics, selectivity, and reversibility collectively determine biological outcome. Relying solely on endpoint Western blot or single-concentration data often masks critical information: a degrader with strong D_max may suffer from slow kinetics that limit cellular activity, while a compound with favorable DC₅₀ may lose selectivity at higher concentrations due to the hook effect. BOC Sciences provides comprehensive degradation ability assay services designed to quantify every dimension of degrader performance — from primary degradation efficiency through mechanistic validation to selectivity profiling — giving medicinal chemistry and biology teams the data resolution needed to make confident lead optimization decisions. Our integrated approach connects degradation data with PROTAC activity assay endpoints, enabling clients to understand not just whether a target is degraded, but how, how fast, how selectively, and with what functional consequence.

BOC Sciences PROTAC Degradation Ability Assay Services

Target Protein Degradation Efficiency Measurement

Quantitative assessment of target protein reduction is the foundation of any degrader characterization program. BOC Sciences employs quantitative Western blot, capillary immunoassay, and multiplexed electrochemiluminescence-based detection platforms to measure both relative and absolute target protein changes. We determine DC₅₀ (the concentration required for 50% degradation) and D_max (maximal degradation achieved) through rigorous dose-response analysis. For programs requiring deeper temporal resolution, we perform time-course experiments spanning early degradation onset to late-stage recovery, tracking protein half-life (t_1/2) reduction. High-content imaging and flow cytometry further enable single-cell resolution degradation quantification, revealing population heterogeneity that bulk measurements may obscure.

Ubiquitin-Proteasome Pathway Validation

Demonstrating that degradation proceeds through the intended ubiquitin-proteasome system (UPS) is essential for confirming mechanism of action. We validate ubiquitination of the target protein by co-immunoprecipitation coupled with ubiquitin-specific antibody detection, confirming that the degrader promotes productive polyubiquitin chain formation on the target. Proteasome dependency is established through rescue experiments using proteasome inhibitors, which should block degradation if the mechanism is UPS-mediated. Our PROTAC ternary complex assay services further confirm that the degrader simultaneously engages both the target protein and the E3 ligase, a prerequisite for productive ubiquitination. E3 ligase specificity is verified through genetic knockout or knockdown approaches or siRNA-mediated knockdown of the relevant ligase (e.g., CRBN, VHL), demonstrating that degradation is abolished in the absence of the specific E3 component.

Degradation Mechanism Validation

Beyond confirming UPS involvement, comprehensive mechanism deconvolution distinguishes proteasomal degradation from alternative clearance routes. We employ lysosomal inhibitors (chloroquine, bafilomycin A₁) in parallel rescue experiments to rule out autophagy-lysosomal pathway contributions. Cycloheximide chase experiments decouple the effects of inhibited protein synthesis from accelerated degradation, ensuring that observed protein level reductions reflect true degradation rather than transcriptional or translational suppression. For programs requiring definitive target engagement evidence, we support mutagenesis studies — introducing point mutations in the target protein or E3 ligase binding interface — to confirm that degradation depends on specific binary interaction surfaces. We also provide in vivo target degradation assessment in relevant research animal models through PROTAC in vivo PD evaluation, connecting cellular degradation data to tissue-level pharmacodynamics.

Selectivity and Hook Effect Analysis

Degradation selectivity and the hook effect are two of the most critical yet frequently under-characterized aspects of degrader pharmacology. We assess selectivity through proteome-wide degradation profiling using quantitative mass spectrometry, identifying unintended degradation events including E3 ligase neo-substrate recruitment (e.g., IKZF1/3 or GSPT1 for CRBN-based degraders). For programs targeting protein families (e.g., kinases, nuclear hormone receptors), we evaluate degradation across homologous family members to establish selectivity windows. The hook effect — where excess degrader concentrations saturate binary binding and inhibit ternary complex formation, producing a bell-shaped degradation curve — is systematically characterized through multi-point dose-response studies. This analysis defines the optimal concentration range for productive degradation and reveals whether the therapeutic window is constrained by hook effect-driven efficacy loss. Our PROTAC selectivity evaluation services integrate these endpoints into a unified selectivity and safety profile.

Key Degradation Parameters and Data Outputs We Provide

DC₅₀ and D_max Determination

DC₅₀ (half-maximal degradation concentration) and D_max (maximal degradation extent) are the two most fundamental parameters quantifying degrader potency and efficacy. We generate full dose-response curves across a wide concentration range, typically spanning sub-nanomolar to micromolar levels, using quantitative Western blot or capillary immunoassay as detection readouts. Data are fitted to standard dose-response models to extract DC₅₀ values with confidence intervals. D_max is reported as the percentage reduction relative to vehicle control, with values typically exceeding 90% for highly effective degraders. For programs comparing multiple candidates, we provide head-to-head DC₅₀ and D_max ranking tables that facilitate objective candidate selection.

• Full dose-response curve generation (8–12 concentrations)
• DC₅₀ calculation with 95% confidence intervals
• D_max reporting as percentage of vehicle control

Degradation Rate and Time to Maximum Effect

Degradation kinetics — how rapidly a degrader eliminates its target — can be as important as degradation depth, particularly for targets with rapid resynthesis rates or short therapeutic windows. We characterize the degradation rate (k_deg) and time to D_max through time-course experiments with sampling at multiple intervals (e.g., 0.5, 1, 2, 4, 8, 24, 48 h). Early time points capture the onset of degradation, while later points define the time required to reach maximal effect. For fast-degrading targets, we offer accelerated sampling protocols with intervals as short as 15 minutes. Rate constants are derived from exponential decay fitting, enabling quantitative comparison of degradation speed across analogs or against target protein half-life.

• Multi-timepoint kinetic profiling (0.5–48 h)
• Degradation rate constant (k_deg) determination
• Time-to-D_max for each candidate and concentration

Duration of Degradation and Target Recovery Profile

Understanding how long degradation persists after compound washout — and how quickly the target protein recovers — is essential for predicting dosing requirements and understanding target biology. We perform washout experiments where cells are treated with degrader, then transferred to compound-free medium and monitored for target protein reappearance over time. Recovery half-life (t_1/2 recovery) and the time required to return to baseline levels are reported. These data are particularly informative when comparing degraders that achieve similar DC₅₀ and D_max values but differ in degradation sustainability. Compounds with prolonged target suppression after washout may offer practical advantages for in vivo research applications where continuous exposure cannot be guaranteed.

• Washout recovery kinetics with multi-timepoint monitoring
• Recovery half-life (t_1/2 recovery) calculation
• Time-to-baseline determination for each candidate

Dose-Response Window and Hook Effect Profile

The hook effect — a hallmark of heterobifunctional degrader pharmacology — occurs when high degrader concentrations saturate binary binding sites, inhibiting productive ternary complex formation and paradoxically reducing degradation. We systematically characterize this phenomenon through extended dose-response studies covering 3–4 log units of concentration, capturing both the ascending (degradation) and descending (hook) phases of the response curve. Key parameters reported include the concentration at maximal degradation (C_{max effect}), the hook onset concentration, and the degradation window width (the concentration range over which degradation exceeds 50% of D_max). This information is critical for selecting lead candidates with broad, practically accessible degradation windows.

• Extended dose-response across 3–4 log concentration range
• Hook onset concentration and degradation window width
• Bell-shaped curve characterization and ternary complex correlation

Isoform and Cell-Type Selectivity

For targets with multiple isoforms or closely related family members, degradation selectivity is a critical parameter influencing both biological interpretation and safety profiling. We compare degradation efficiency across target isoforms (e.g., AKT1 vs. AKT2 vs. AKT3, or BRD2 vs. BRD3 vs. BRD4 vs. BRDT) using isoform-specific antibodies or tagged protein expression systems. Cell-type selectivity is assessed by profiling degradation in multiple relevant cell lines — including disease-relevant models, normal control lines, and cell lines with varying E3 ligase expression levels — to determine whether degradation efficiency is context-dependent. These data help identify degraders with optimal selectivity profiles and inform the choice of cell models for downstream pharmacology studies.

• Isoform-specific degradation comparison across protein families
• Multi-cell-line degradation profiling (3–6 cell lines typical)
• E3 ligase expression-correlated degradation analysis

Degradation-to-Phenotype Correlation

The ultimate value of degradation data lies in its ability to explain and predict cellular phenotype. We integrate degradation parameters with downstream functional readouts — including cell viability, proliferation, apoptosis, pathway biomarker changes, and transcriptional responses — to establish quantitative degradation-to-phenotype relationships. This analysis helps distinguish whether observed cellular effects are driven by target degradation (on-mechanism) or by compound-intrinsic properties (off-mechanism), and identifies the degradation depth or duration required to achieve a desired biological response. For programs transitioning from in vitro to in vivo studies, our PROTAC in vivo evaluation services extend this correlation to tissue-level pharmacodynamic endpoints.

• Degradation depth vs. functional response correlation curves
• On-mechanism vs. off-mechanism effect discrimination
• Minimal degradation threshold for biological activity determination

BOC Sciences Degradation Assays by Molecular Degrader Modality

PROTAC and Heterobifunctional Degrader Assessment

Heterobifunctional PROTACs represent the most mature and widely studied TPD modality. Our assay platform for PROTACs centers on ternary complex-dependent degradation quantification, combining dose-response DC₅₀/D_max determination with ternary complex formation analysis to confirm the catalytic degradation mechanism. We systematically evaluate the influence of linker composition, length, and attachment chemistry on degradation efficiency and kinetics. Hook effect characterization is performed as a standard component of PROTAC profiling, given its direct relevance to ternary complex stoichiometry. For programs exploring multiple E3 ligase recruiters, we offer PROTAC design services-informed parallel testing across CRBN-, VHL-, IAP-, and MDM2-based constructs to identify the optimal degrader architecture for a given target.

Molecular Glue Degradation Assessment

Molecular glues operate through a mechanistically distinct paradigm — inducing or stabilizing novel protein-protein interactions between an E3 ligase and a target protein that lacks a pre-existing binding pocket for the ligase. Degradation assays for molecular glues require particular attention to cooperativity: unlike PROTACs, molecular glues often display shallow or non-sigmoidal degradation curves reflecting their lower-affinity ternary complex stabilization. We adapt dose-response protocols to capture these unique pharmacological features, and routinely include binding affinity measurement of the induced E3–target interface to correlate binding enhancement with degradation efficiency. Neo-substrate identification through global proteomics is integrated as a key component of molecular glue characterization, given the inherent challenge of predicting which proteins will be recruited to a given E3 ligase.

LYTAC, AbTAC, and Extracellular Degrader Assessment

Lysosome-targeting chimeras (LYTACs), antibody-based TACs (AbTACs), and other extracellular degradation modalities target proteins residing on the cell surface or in the extracellular space, routing them to the lysosome rather than the proteasome. Degradation assays for these modalities require pathway-specific validation distinct from UPS-focused protocols. We confirm lysosomal routing through colocalization studies with lysosomal markers and demonstrate pathway dependence using lysosomal inhibitors (bafilomycin A₁, chloroquine) in rescue experiments. Degradation kinetics for extracellular targets often differ substantially from intracellular PROTACs due to receptor-mediated endocytosis rate-limiting steps; our time-course protocols are adjusted accordingly with extended monitoring windows. Surface protein degradation is quantified by flow cytometry or cell-surface ELISA in addition to total protein measurement.

AUTAC, ATTEC, and Autophagy-Based Degrader Assessment

AUTACs (autophagy-targeting chimeras) and ATTECs (autophagosome-tethering compounds) harness the autophagy-lysosome pathway to degrade targets including protein aggregates, damaged organelles, and lipid droplets — cargoes inaccessible to the UPS. Degradation assays for these modalities require autophagy-specific validation: we confirm autophagic flux dependence using autophagy inhibitors (3-methyladenine, chloroquine) and monitor autophagosome marker (LC3-II) conversion alongside target degradation. For mitochondrial targets, we combine protein degradation measurement with organelle health readouts (membrane potential, ROS production). ATTEC-mediated degradation of aggregate-prone proteins requires solubility-adapted detection methods and extended treatment durations. We develop assay strategies according to the supplied degrader modality, target biology, and pathway-specific readout requirements.

CLIPTAC, Light-Controllable, and Conditional Degrader Assessment

Conditionally activated degraders — including CLIPTACs (click-formed PROTACs), photocaged PROTACs, and other stimuli-responsive constructs — introduce spatiotemporal control over degradation but add complexity to assay design. Degradation assays for these modalities must include activation controls (light exposure, bioorthogonal reaction initiation) and demonstrate that degradation is conditional upon the triggering stimulus. We design protocols that compare degradation in activated vs. non-activated conditions, quantify activation efficiency, and characterize the degradation time course following trigger application. For light-controllable systems, we offer wavelength-specific and pulsed-illumination protocols. These specialized assays help clients validate that their conditional degradation strategy provides the intended control over target protein elimination.

Covalent, Homo-PROTAC, and Peptide-Based Degrader Assessment

Covalent PROTACs, Homo-PROTACs (E3 ligase self-degraders), and peptide-based degraders each present unique assay considerations. Covalent degraders require confirmation of target engagement irreversibility and washout-resistant degradation, which we assess through extended post-washout monitoring and target engagement competition experiments. Homo-PROTACs — designed to degrade E3 ligases themselves — demand careful E3 ligase activity monitoring alongside degradation quantification to confirm functional ligase depletion. Peptide-based degraders, including phospho-dependent and motif-directed constructs, require solubility and stability assessment as integral components of the degradation assay, as peptide stability often governs apparent degradation efficiency. Our platform adapts standard protocols to address these modality-specific requirements.

Applications of Degradation Ability Assays

Our PROTAC Degradation Ability Assay Workflow

Why Choose BOC Sciences for Degradation Ability Assays?

PROTAC-Specific Assay Design Expertise

We do not apply generic small-molecule assay logic to degraders. Every assay is designed with an understanding of ternary complex kinetics, catalytic turnover, hook effect behavior, and the interplay between degradation depth and cellular phenotype — ensuring that the data generated are meaningful for degrader optimization, not just protein quantification.

Multiple Orthogonal Quantification Platforms

From quantitative Western blot and capillary immunoassay to multiplexed electrochemiluminescence platforms, global proteomics, high-content imaging, and flow cytometry — our multi-platform capability allows us to select the optimal detection technology for each target and question, and to cross-validate key results through orthogonal approaches.

Flexible Throughput and Compound-Sparing Strategies

Whether your program needs high-throughput screening of hundreds of analogs or deep mechanistic profiling of a handful of leads, our workflow adapts. We offer miniaturized assay formats that conserve precious compound, and tiered profiling strategies that apply higher-resolution methods only to the most promising candidates.

Integrated Chemistry and Biology Interpretation

Degradation data are most valuable when connected to molecular design. Our scientists interpret degradation results in the context of degrader structure — linker composition, warhead binding mode, E3 ligase choice — providing actionable recommendations for the next design iteration rather than isolated assay readouts.

Target-Class and Cell-Model Customization

Assay conditions are tailored to your target biology. We customize cell models (disease-relevant lines, E3 ligase expression-matched lines, isogenic controls), treatment protocols, and detection strategies based on target abundance, turnover rate, subcellular localization, and the specific biological context of your research program.

Actionable Structure-Degradation Guidance

Every report includes not just data tables and dose-response curves, but practical interpretation: which degradation parameters differentiate your lead candidates, which structural features correlate with degradation performance, and where the next optimization opportunities lie. Our PROTAC off-target evaluation and PROTAC cellular permeability assay services can be integrated to provide an even more complete candidate profile.

Client Success Stories in PROTAC Degradation Assessment

Client Testimonials on Our Degradation Ability Assays